Clinical trial dosing will resume around year-end 2017. Source: BioSpace

Industry analysts were shocked when in July the FDA reversed course on Amicus' Phase III treatment for Fabry disease. Source: BioSpace

Now that 2017 is drawing to an end, though, it's time to focus on the new year. Source: BioSpace

Boehringer's global head of information technology, Michael Schmelmer, will replace Menne on Jan. 1, 2018. Source: BioSpace

Merck's Keytruda came up short in a pivotal Phase III trial as a second-line treatment for patients with advanced gastricadenocarcinoma or GEJ adenocarcinoma. Source: BioSpace

Biotechs are taking notice as a new pool of funding is being made available by venture capital Andreesen Horowitz. Source: BioSpace

Asklepios BioPharma is forming a new biotech portfolio company, Actus Therapeutics. Source: BioSpace

Perrigo is expected to face competition from Swiss food giant Nestle and the private equity owners of German drug firm Stada. Source: BioSpace

The approval was based on data from the Phase 3 Oral Psoriatic Arthritis Trial (OPAL) clinical development program. Source: BioSpace

argenx increased the Offering from the initially filed offering size of $150 million. Source: BioSpace